Everything Lupus: Resource Hub
NATIONAL ADVISORY COMMITTEE OF IMMUNIZATION (NACI) RAPID RESPONSE: ADDITIONAL DOSE OF COVID-19 VACCINE IN IMMUNOCOMPROMISED INDIVIDUALS FOLLOWING 1- OR 2- DOSE PRIMARY SERIES
Read
If you’re moderately to severely immunocompromised due to disease or treatment,
Read
Canadian Lupus Registry
Read
Ontario individuals who are immunocompromised can get a fourth dose
Read
Government of Canada signs new COVID-19 antibody therapy agreement
Read
Canadian Rheumatology Association Position Statement on COVID-19 Vaccination
Read
Canadian Rheumatology Association Improves Outcomes In SLE
Read
Lupus Canada is pleased to share that Health Canada has approved Evusheld for pre-exposure prophylaxis of COVID-19 in immune-compromised individuals.
Read
GSK’s Belimumab shows significant improvement in renal function in the largest Lupus Nephritis (LN) clinical study
Read
Evusheld authorized by Health Canada
Read
AstraZeneca’s Anifrolumab demonstrated early and sustained reduction of disease activity in SLE patients in the Phase III Tulip clinical trial
Read
From Manchester to Toronto – Improving lupus ‘brain fog’
Read
